Collection of cerebrospinal fluid for cognitive disorder research
Official title: Analysis of Clinical Data and Diagnosis in Any Person Requiring an Assay of Alzheimer Biomarkers in Cerebrospinal Fluid
Run by University Hospital, Strasbourg, France · NCT04844060 · Data updated 2026-11-12
This study is collecting spinal fluid from people with cognitive disorders like Alzheimer's and dementia to help improve how these diseases are diagnosed.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | February 2010 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | April 27, 2023 |
| Trial ID | NCT04844060 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with a confirmed clinical diagnosis of cognitive neurodegenerative diseases who are undergoing lumbar puncture.
✕Probably not a fit
Patients who do not require a lumbar puncture or lack accurate diagnostic information may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on collecting cerebrospinal fluid (CSF) from patients diagnosed with various cognitive neurodegenerative diseases, including Alzheimer's disease and dementia. The aim is to create a CSF library that can help improve diagnostic accuracy and reduce errors associated with these conditions. By analyzing CSF biomarkers, researchers hope to enhance the understanding of these diseases and facilitate earlier and more accurate diagnoses. The study involves lumbar punctures for fluid collection from eligible patients with confirmed clinical diagnoses.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for cognitive disorders, reducing misdiagnosis and enhancing patient care.
How similar studies have gone: Other studies utilizing CSF biomarkers have shown promise in improving diagnostic accuracy for neurodegenerative diseases, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with lumbar puncture (LP) * Patients with accurate clinical diagnosis Exclusion Criteria: * Patients who do not have a lumbar puncture * Patients for whom no accurate diagnostic information is available
Where it's running
-
Service d'évaluation et Centre Mémoire de Ressources et de Recherche (CM2R), Hôpital de jour Saint François - Pôle de Gériatrie, Hôpitaux Universitaires de Strasbourg, Hôpital de la Robertsau
Strasbourg, France Recruiting
Study contacts
- Principal investigator: Frédéric BLANC, MD/PhD — Hôpitaux Universitaires de Strasbourg
- Study coordinator: Frédéric BLANC, MD/PhD
- Email: frederic.blanc@unistra.fr
- Phone: 33388155858
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting disease progression in dementia using biomarkers and modeling
This study is trying to create a tool that helps predict how dementia will progress in people with mild cognitive impairment and different types of dementia, like Alzheimer's and Lewy Body Disease, by looking at brain scans, body fluids, and mental tests.
-
Biobank for studying ALS and Alzheimer's diseases
This study is collecting blood, skin samples, and health information from people to see how genetics might help us understand and find treatments for ALS and Alzheimer's disease.
-
Non-invasive brain stimulation for neurodegenerative diseases
This study is testing if a new type of brain stimulation can help relieve symptoms in people with neurodegenerative diseases like Alzheimer's and dementia.
-
Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes
This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.
-
ARO-MAPT-SC in healthy adults and people with early Alzheimer's disease
This trial will test whether ARO-MAPT-SC is safe, tolerable, and produces the expected drug levels and biomarker effects in healthy adults and people with early Alzheimer's disease.
-
Collecting data on neurodegenerative diseases progression markers
This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.